Streetbeat News

Analyst Ratings

TERN

JMP Securities has maintained a Market Outperform rating on Terns Pharma and increased its price target from $15 to $20.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:58 am

PROK

ProKidney shares rose following Guggenheim's initiation of coverage with a Buy rating and a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:55 am

TSLA

Deutsche Bank analyst Edison Yu has reinstated a Buy rating on Tesla (NASDAQ:TSLA) and set a price target of $295.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:55 am

BOOT

BTIG analyst Janine Stichter maintains a Buy rating on Boot Barn Holdings and raises the price target from $150 to $165.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:54 am

CNTA

ORCL

VRDN

Oracle shares rose 9% after strong Q1 results and an upgrade by JMP Securities. Viridian Therapeutics saw a 16% increase following positive phase 3 trial data for VRDN-001. Centessa Pharmaceuticals' stock jumped 18% due to promising interim data from a phase 1 trial of ORX750.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:52 am

ORCL

BMO Capital has maintained its Market Perform rating on Oracle and raised the price target from $160 to $173, indicating a positive outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:52 am

BNGO

BTIG analyst Mark Massaro has downgraded Bionano Genomics (NASDAQ:BNGO) from a Buy to a Neutral rating.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:49 am

ORCL

Oracle shares rise as Q1 financial results exceed expectations, leading to an upgrade by JMP Securities from Market Perform to Market Outperform.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:48 am

HAE

BTIG has initiated coverage on Haemonetics with a Buy rating and set a price target of $112, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:42 am

JCI

B of A Securities has upgraded Johnson Controls Intl (NYSE:JCI) from Neutral to Buy, raising the price target from $76 to $80.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:42 am